GIP and GLP-1 as treatment targets in type 2 diabetes and obesity: a dual incretin perspective — VialBase Research

Summary

Authoritative review exploring the rationale for dual incretin agonism (GIP + GLP-1) in the treatment of type 2 diabetes and obesity. Examines why adding GIP receptor agonism to GLP-1 (as tirzepatide does) produces superior metabolic outcomes compared to GLP-1 agonism alone (as semaglutide provides).

Key Findings

• GIP and GLP-1 act through complementary but distinct receptor pathways
• GIP receptor agonism enhances central nervous system appetite regulation beyond GLP-1 effects
• GIP contributes to improved beta-cell function and insulin sensitivity
• Dual agonism may improve GI tolerability compared to high-dose GLP-1 alone
• Explains the clinical superiority of tirzepatide over semaglutide in SURPASS-2
• GIP receptor in adipose tissue may improve fat metabolism and storage

Methodology

Expert review article synthesizing basic science, animal model, and clinical trial data examining GIP and GLP-1 receptor biology and their combined pharmacological effects.

Limitations

• Mechanistic understanding of GIP receptor’s contribution still evolving
• Relative contribution of GIP vs GLP-1 components difficult to isolate in clinical data
• GIP receptor agonism was historically thought to be obesogenic — paradigm shift still debated
• No clinical studies isolating GIP agonism alone in obesity
• Long-term implications of dual agonism unknown

Relevance to Content

Essential for explaining “why tirzepatide works better than semaglutide” in mechanistic terms. The dual agonism story provides scientific depth for comparison content. Also positions the evolution from single to dual to triple agonism (semaglutide → tirzepatide → retatrutide) as a compelling narrative arc.

See Also

• Parent compound: Tirzepatide
• Semaglutide
• Retatrutide